Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-transfected Dendritic Cells in HIV-1
NCT00833781Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2009
- Primary completion
- Dec 2013
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mRNA-transfected autologous dendritic cells in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Safety of the DC Vaccine (Frequency of Adverse Events) and Change From Baseline to Week 14 in ELISPOT Response to Gag and Nef. Started Aug 2009; status: completed.
02
Drugs
mRNA-transfected autologous dendritic cells
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00833781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00833781.